Davidn Cade News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Davidn Cade. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Davidn Cade Today - Breaking & Trending Today

Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer

Published: May 31, 2024

TLX591 is an investigational anti-PSMA[1] radio-antibody-drug conjugate rADC therapy being developed for the treatment of mCRPC differentiated by a short two-week dosing regimen Reported median radiographic progression-free survival rPFS is 88 months Builds on prior data from the ProstACT SELECT[2] trial demonstrating favourable safety profile and biodistribution[3] MELBOURNE Australia May 31 2024 PRNewswire --Telix Pharmaceuticals Limited ASX TLX Telix the Company today announces additional positive datafrom the ProstACT SELECT trial SELECT of TLX591 177Lu rosopatamab tetraxetan a lutetium-la...

Source: bignewsnetwork.com

Related Topics:

Telix (ASX:TLX) Advances in Prostate Cancer Treatment

Published: May 22, 2024

Telix Pharmaceuticals (ASX: TLX) has completed the CUPID study, a Phase I trial on its investigational drug TLX592 for prostate cancer patients

Source: thebull.com.au

Related Topics:

Davidn Cade Telix Pharmaceuticals Sonic Healthcare

Telix Pharmaceuticals Limited: Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer

Published: May 21, 2024

CUPID is a Phase I safety and dosimetry study of TLX592, Telix's investigational antibody-based targeted alpha therapy for prostate cancer.Establishes proof-of-concept for Telix's proprietary

Source: finanznachrichten.de

Related Topics:

United States Davidn Cade Kyahn Williamson Telix Pharmaceuticals Limited Corporate Communications Telix Pharmaceuticals Limited Disclosure Committee Health Canada Australian Therapeutic Goods Administration Australian Securities Exchange Telix Pharmaceuticals Drug Administration Prnewswire Telix Pharmaceuticals Limited Pharmaceuticals Limited Positron Emission Tomography Group Chief Medical Officer Ihr Portfolio

Telix Completes Proof-Of-Concept Study Of TLX592 Targeted Alpha Therapy In Prostate Cancer

Published: May 21, 2024

Source: menafn.com

Related Topics:

United States Kyahn Williamson Davidn Cade Health Canada Prnewswire Telix Pharmaceuticals Limited Drug Administration Australian Securities Exchange Telix Pharmaceuticals Limited Disclosure Committee Telix Pharmaceuticals Telix Pharmaceuticals Limited Corporate Communications Australian Therapeutic Goods Administration Pharmaceuticals Limited Positron Emission Tomography Group Chief Medical Officer

Telix Pharmaceuticals Limited: Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer

Published: January 1, 2024

TLX591 is an investigational anti-PSMA[1] radio-antibody-drug conjugate (rADC) therapy being developed for the treatment of mCRPC, differentiated by a short two-week dosing regimen.Reported

Source: finanznachrichten.de

Related Topics:

United States Nat Lenzo Kyahn Williamson Davidn Cade Nuclear Oncologist Telix Pharmaceuticals Drug Administration Telix Pharmaceuticals Limited Disclosure Committee Health Canada Telix Pharmaceuticals Limited Australian Therapeutic Goods Administration Corporate Communications Australian Securities Exchange Prnewswire Telix Pharmaceuticals Limited Pharmaceuticals Limited General Internal Medicine Physician Group Chief Medical Officer Nuc Med Ihr Portfolio

Page 2 Page 3 Page 4 Page 5